Hypersensitivity Reactions to Oxaliplatin: Clinical Features and Risk Factors in Koreans |
Kim, Mi-Yeong
(Department of Internal Medicine, Seoul National University College of Medicine)
Kang, Sung-Yoon (Department of Internal Medicine, Seoul National University College of Medicine) Lee, Suh-Young (Department of Internal Medicine, Seoul National University College of Medicine) Yang, Min-Suk (Department of Internal Medicine, Seoul National University College of Medicine) Kim, Min-Hye (Department of Internal Medicine, Seoul National University College of Medicine) Song, Woo-Jung (Department of Internal Medicine, Seoul National University College of Medicine) Kim, Sae-Hoon (Department of Internal Medicine, Seoul National University College of Medicine) Kim, Yo-Jung (Department of Internal Medicine, Seoul National University College of Medicine) Lee, Keun-Wook (Department of Internal Medicine, Seoul National University College of Medicine) Cho, Sang-Heon (Department of Internal Medicine, Seoul National University College of Medicine) Min, Kyung-Up (Department of Internal Medicine, Seoul National University College of Medicine) Lee, Jong-Seok (Department of Internal Medicine, Seoul National University College of Medicine) Kim, Jee-Hyun (Department of Internal Medicine, Seoul National University College of Medicine) Chang, Yoon-Seok (Department of Internal Medicine, Seoul National University College of Medicine) |
1 | Andre T, Boni C, Mounedji-Boudiaf L, et al (2004). Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med, 350, 2343-51. DOI ScienceOn |
2 | Bajetta E, Pietrantonio F, Di Bartolomeo M, Buzzoni R (2010). Acute immune-mediated thrombocytopenia due to oxaliplatin administration: a case report. Tumori, 96, 154-6. |
3 | Basu R, Rajkumar A, Datta NR (2002). Anaphylaxis to cisplatin following nine previous uncomplicated cycles. Int J Clin Oncol, 7, 365-7. DOI |
4 | Bautista MA, Stevens WT, Chen CS, et al (2010). Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J Hematol Oncol, 3, 12. DOI |
5 | Bhargava P, Gammon D, McCormick MJ (2004). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 100, 211-2. DOI |
6 | Brandi G, Pantaleo MA, Galli C, et al (2003). Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer, 89, 477-81. DOI ScienceOn |
7 | Collet E, Leguy-Seguin V, Jolimoy G, et al (2007). Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immun, 119, 726-30. DOI |
8 | Faivre S, Chan C, Salinas R, et al (2003). DNA strand breaks and apoptosis induced by oxaliplatin in cancer cells. Biochem Pharmacol, 66, 225-37. DOI |
9 | Garufi C, Cristaudo A, Vanni B, et al (2003). Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol, 14, 497-8. DOI |
10 | Gowda A, Goel R, Berdzik J, et al (2004). Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology, 18, 1671-5; discussion 6, 80, 83-4. |
11 | Ichikawa Y, Goto A, Hirokawa S, et al (2009). Allergic reactions to oxaliplatin in a single institute in Japan. Jpn J Clin Oncol, 39, 616-20. DOI |
12 | Kelland L (2007). The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer, 7, 573-84. DOI |
13 | Kidera Y, Satoh T, Ueda S, et al (2011). High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol, 16, 244-9. DOI |
14 | Kim BH, Bradley T, Tai J, Budman DR (2009). Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology, 76, 231-8. DOI |
15 | Koren C, Yerushalmi R, Katz A, et al (2002). Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol, 25, 625-6. DOI |
16 | Lee KH, Park YJ, Kim ES, et al (2006). Hypersensitivity reactions to oxaliplatin. Cancer Res Treat, 38, 240-1. DOI |
17 | Lee MY, Yang MH, Liu JH, et al (2007). Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer, 15, 89-93. DOI |
18 | Lim KH, Huang MJ, Lin HC, et al. (2004). Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. Anticancer Drugs, 15, 605-7. DOI |
19 | Makrilia N, Syrigou E, Kaklamanos I, et al (2010). Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs, ??, ??. |
20 | Maindrault-Goebel F, Andre T, Tournigand C, et al. (2005). Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer, 41, 2262-7. DOI |
21 | Markman M, Kennedy A, Webster K, et al (1999). An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol, 125, 427-9. DOI |
22 | Mason JM, Rees G (2010). Oxaliplatin-induced acute thrombocytopenia. J Oncol Pharm Pract, 17, 433-5. |
23 | Morgan JS, Adams M, Mason MD (1994). Hypersensitivity reactions to carboplatin given to patients with relapsed ovarian carcinoma. Eur J Cancer, 30A, 1205-6. |
24 | Petit-Laurent F, Conroy T, Krakowski I, et al (2000). [Delayed urticaria with oxaliplatin]. Gastroenterol Clin Biol, 24, 851-2. |
25 | Polyzos A, Tsavaris N, Gogas H, et al (2009). Clinical features of hypersensitivity reactions to oxaliplatin: a 10- year experience. Oncology, 76, 36-41. DOI |
26 | Polyzos A, Tsavaris N, Kosmas C, et al (2001). Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology, 61, 129-33. DOI |
27 | Santini D, Tonini G, Salerno A, et al (2001). Idiosyncratic reaction after oxaliplatin infusion. Ann Oncol, 12, 132-3. DOI |
28 | Shao YY, Hu FC, Liang JT, et al. (2010). Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions. J Formos Med Assoc, 109, 362-8. DOI |
29 | Siu SW, Chan RT, Au GK (2006). Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol, 17, 259-61. DOI |
30 | Shibata Y, Ariyama H, Baba E, et al (2009). Oxaliplatininduced allergic reaction in patients with colorectal cancer in Japan. Int J Clin Oncol, 14, 397-401. DOI |
31 | Thomas RR, Quinn MG, Schuler B, Grem JL (2003). Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 97, 2301-7. DOI |
32 | Trotti A, Colevas AD, Setser A, et al (2003). CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol, 13, 176-81. DOI |
33 | Villee C, Tennstedt D, Marot L, et al (2010). Delayed urticaria with oxaliplatin. Contact Dermatitis, 63, 50-3. DOI |
34 | Zanotti KM, Rybicki LA, Kennedy AW, et al (2001). Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol, 19, 3126-9. |
![]() |